Loading
Virus-based Gene Therapy Research / RNA Interference and Gene Delivery / Cancer Research and Treatments · Journal article
Molecular Cancer · September 8, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes the evolving landscape of mRNA cancer therapeutics across molecular design, delivery platforms, and clinical modalities. It frames mRNA oncology as an integrated programmable system requiring coordinated optimization of RNA engineering, delivery, payload pharmacology, and tumor-immune interactions, but does not report new clinical data or compare efficacy outcomes.
Journal article.
mRNA therapeutics have transitioned from a technically constrained modality to a clinically validated platform in oncology Major clinical applications include universal and personalized vaccines, encoded antibodies and bispecifics, cytokines, immune modulators, and ex vivo and in vivo cell-engineering strategies Key design constraints include balancing transgene expression with immune activation, controlling local versus systemic activity, ensuring targeting specificity, and optimizing antigen selection and presentation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should read this as an expert synthesis of design principles and clinical landscape for mRNA cancer therapeutics, useful for understanding the modality's trajectory and current applications, but not as evidence of efficacy in any specific indication.
A comprehensive review synthesizing the state of mRNA cancer therapeutics across design, delivery, and clinical translation—expert framing rather than a new empirical finding.
Clinicians and researchers should read this as an expert synthesis of design principles and clinical landscape for mRNA cancer therapeutics, useful for understanding the modality's trajectory and current applications, but not as evidence of efficacy in any specific indication.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Messenger RNA (mRNA) therapeutics have evolved from a technically constrained modality into a clinically validated platform for vaccination that is increasingly being explored in oncology. The field is no longer defined by whether mRNA can encode therapeutic proteins, but by how RNA expression can be controlled across spatial, dose, duration, and immune context to achieve therapeutic benefit. This review frames mRNA cancer therapeutics as integrated programmable systems that link RNA architecture, delivery technologies, payload pharmacology, immune interactions, manufacturing and clinical translation. We discuss major mRNA modalities and examine lipid nanoparticles together with emerging delivery platforms, with particular attention to extrahepatic targeting, endosomal escape, repeat dosing, and cell-type specificity. We then summarize the clinical landscape of mRNA-based cancer therapies, including universal and personalized vaccines, encoded antibodies and bispecifics, cytokines and immune modulators, and ex vivo and in vivo cell-engineering strategies. Across these applications, key design constraints include balancing transgene expression with immune activation, controlling local versus systemic activity, ensuring targeting specificity, and optimizing antigen selection and presentation. We propose that mRNA cancer therapeutics are diverging into modality-specific solutions in which clinical efficacy depends on coordinated optimization of RNA engineering, productive delivery, payload pharmacology, and tumor-immune biology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.